prognosis in patients with multiple myeloma and renal involvement. Maintenance haemodialysis is a Background. The prognosis of monoclonal gammopathies with multiple myeloma and renal involvement reasonable indication in light chain deposit disease and AL-amyloidosis, especially in patients aged <70. is poor, and the indication for renal replacement therapy is controversial. Few studies address the value Multidrug therapy tends to prolong survival and slow progression to end-stage renal disease. of renal histology for determining prognosis according to initial pathology findings.
Introduction
End-points were death, or survival on dialysis, or serum creatinine level at last examination.
Two decades ago, renal insufficiency in the course of Results. Renal biopsy showed myeloma kidney in 48 monoclonal gammopathies (MG) heralded poor procases (41%), AL-amyloidosis in 35 (30%), light chain gnosis and survival was a matter of months [1] . deposit disease in 22 (19%) , chronic tubulointerstitial Presently, a number of patients survive for years with nephritis in 12 (10%) and cryoglobulinaemic kidney dialysis, provided they respond to chemotherapy [2] [3] [4] [5] [6] [7] [8] [9] . with multiple myeloma in 1. Maintenance haemoThis leads to the hope that radical treatment of myeldialysis was required in 46 patients (39%), earlier oma-related conditions may obtain survival rates com-(P<0.0001) in myeloma kidney (mean: 3 months after parable to those of patients with end-stage renal disease diagnosis) than in AL-amyloidosis (mean: 15 months) due to non-malignant conditions. However, better and light chain deposit disease (mean: 18 months).
knowledge of the visceral complications of B cell Median survival was 12 months in myeloma kidney, proliferation has widened the spectrum of what was 24 months in AL-amyloidosis and 48 months in light uniformly called 'myeloma kidney' in the past. Renal chain deposit disease. Dialysis increased survival in involvement in monoclonal gammopathies can now light chain deposit disease, in contrast with myeloma be distinguished as myeloma kidney (MK ), ALkidney and AL-amyloidosis patients whose survival amyloidosis (AL) and light chain deposit disease was shorter when dialysed. The main cause of death (LCDD) [5, [10] [11] [12] [13] . Renal biopsy is essential to distinduring first year of dialysis was cardiac involvement in guish these subsets. The goal of this study is to show AL-amyloidosis, and sepsis or cardiac insufficiency in that initial renal histology ranks among the predictors myeloma kidney. There was a trend to increased surof survival in patients with B cell malignancy and vival with multidrug chemotherapy which seemed to should be taken into account in the indications of slow progression to end-stage renal failure. At last maintenance haemodialysis. follow-up (median: 12 months, range 1-297), 65 (55%) patients had died. By multivariate analysis, independent predictors of survival were: age <70, serum creatin- Table 1 . Main clinical features in 118 patients with renal histological mia and chronic lymphocytic leukaemia were excluded, as lesions due to monoclonal gammopathies were those with a monoclonal gammopathy of undetermined significance. All patients had biopsy-proven renal lesions due to MG [14] . [15] . MK was more frequently found in stage 3 patients, whereas amyloidosis was patients (59%) and an isolated light chain (24 k/19 l) in 43 patients (36%). In the five others, a monoclonal mainly present in stage 1 and never in stage 3. LCDD was evenly distributed among stages. light chain was only found in urine ( Table 1) . Initial haemoglobin levels were 10.3±2.5 g/dl (range:
Haemodialysis was required in 52 patients, within a few days in 23, transiently in 6 (11.5%) and perman-4.1-18.2). MG was revealed by acute renal failure in 31 patients (26%). At presentation, serum creatinine ently in 46 (88.5%) ( Table 1) . Maintenance haemodialysis was needed within a median period of 2 months was 457±407 mmol/l, proteinuria was 4.6±4.2 g/24 h, and serum albumin was 32.0±9.4 g/l.
after the first symptoms in 39% of all MG cases, and in 81% of them during the first year of renal involve- Table 2 shows the renal pathological appearance in 118 patients with MG. Forty-eight had a pattern of ment. One patient received a renal transplant. Figure 1 gives the survival curve for the three groups. Patients with MK had high initial mortality (24% at 2 Median follow-up was 12 months (range: 1-297) until months), but subsequent mortality was lower, with a death or last examination. Sixty-five patients (55%) median survival rate of 12 months. No death was died a median of 11 months (range: 1-88) after the observed during the first year in LCDD patients whose first renal symptoms, and the remaining 53 were fol-median survival reached 36 months. Patients with lowed during 18 months (range: 1-297).
Follow-up and treatment
amyloidosis had an intermediate course (median Chemotherapy was given to 91 of 118 patients. survival: 24 months). Twenty-eight received melphalan and prednisone, Cardiovascular disease, i.e. cardiac insufficiency, according to Alexanian's protocol [16 ] , 20 cyclophoscardiac arrythmias or sudden death, was the primary phamide and prednisone, 2 steroids alone, 2 alphacause of death in patients with amyloidosis (47%) and interferon alone, and 39 multidrug chemotherapy occurred in 27% of MK and 22% of LCDD patients. including steroids, an alkylating agent, and various Infection was responsible for 27% of deaths in MK types of cytostatic drugs (mainly VAD or VMCP).
and 16% of deaths in amyloidosis. Withdrawal of Among untreated patients, 46% developed ESRD, dialysis accounted for 13% of total fatalities ( Table 5 ). compared to 45% of those treated with steroids and Persistence of mild chronic proteinuria with nearly one alkylating agent and 24% (P=0.06) of those normal renal function was more common in patients treated with combined chemotherapy. Multidrug with amyloidosis than in those with the others chemotherapy was used not only in patients with a (P=0.01). high tumour mass (95% of those with a stage 3 were Dialysis was started earlier in cases of MK (3 so treated) but also in those with a rapidly progressive months) than in those with LCDD (18 months, renal failure, in whom dialysis was started within 2±3 P=0.001) and amyloidosis (15 months, P<0.001) months vs >1 year in those receiving more conven- ( Table 4) . Once dialysed, patients with LCDD had a tional chemotherapy (P<0.01).
better survival rate (43%) than those with MK (14%) Mortality tended to be higher in dialysis patients and amyloidosis (29%), and death occurred in them previously treated with multidrug chemotherapy (80% later than in any other group (mean: 35 vs 9 and 10 vs 66% in those receiving other regimens, NS), but months, respectively). Kaplan and Meier's curve shows mean survival rate was prolonged to 21 months, comthat dialysis patients with MK had a higher mortality pared to 17 months in those treated by steroids and alkylating agents and 11 months in those receiving no within the first month (38%) and only 9% of them chemotherapy. Infection was the primary cause of survived at 4 years ( Figure 2 ). The percentage of death in the multidrug-treated patients (29%) vs 13% survivors at 4 years was 15% in dialysis patients with of the steroid and alkylating group and 6% of non-amyloidosis, the main cause of death being an amyloid treated patients.
cardiac disease, and 50% in LCDD dialysis patients. Chemotherapy was continued in only 12 of 42 In overall dialysis patients, cardiac disease remained dialysed patients, mainly in those with myeloma kidney the first cause of death. and in none with amyloidosis. After start of dialysis, median survival was 9 months in treated patients versus 3 months in the non-treated group (NS).
Outcome according to cell mass At the end of follow-up period, 32 (70%) of dialysis patients had died within a median of 2 months (range : Tables 6 and 7 compare clinical and laboratory features 1-76), and 14 patients survived. Survival beyond the and outcome in the three patient groups according to first year of dialysis was inversely correlated with age tumor mass. Median serum creatinine level at presenta-(59±5 years in survivors vs 69±10 in non-survivors, tion was higher in stage 3 patients (550 mmol/l ) than P=0.02). No patient older than 70 survived. The in those staged 2 (366 mmol/l ) or 1 (160 mmol/l, median duration of dialysis treatment was 9 months P<0.0001). Acute renal failure was more common in (range: 1-87) in younger patients. stage 3 (44%) than in stage 2 (29%) and stage 1 (10%) Comparing our results over years, we were unable (P<0.001). Amyloidosis was present in 62.5% of stage to find any significant change in staging, renal histo-1 patients, but in only 16% in stage 2 and in none of logical picture, renal survival, policy of dialysis, and stage 3 ( Table 2 ). LCDD was equally distributed influence of chemotherapy, multidrug or not, but the among stages. Not surprisingly, MK was found in 69% number of patients in each subgroup was often small. of patients staged 3, but in only 10% of those staged 1 (P<0.01).
Clinical and pathological correlations
Although the mortality rate did not differ among the 3 groups, death was mainly due to amyloid cardiac Tables 3 and 4 describe the patients according to types disease in stage 1 (53%), and to infection in stage 3 of renal lesions (MK, AL-amyloidosis and LCDD).
(46%). Stage 3 MK patients required early dialysis Their age was comparable. Males were predominant (P<0.01). Median survival was 24 months for stage in the LCDD group. MK patients had the lowest 1, 18 months for stage 2 and 12 months for stage 3. haemoglobin and the highest serum calcium levels and Once dialysed, median survival for patients staged 1, nearly half presented with acute renal failure. Mortality was similar in the three groups.
2 and 3 was 18, 6 and 2 months, respectively (P<0.01). Predictors of survival at the time of diagnosis of MM [17] . However, the figures vary according to the source of information. In Multivariate analysis yielded three independent pre-large haematological series [18, 19] , severe renal failure dictors of better survival: age <70, serum calcium is found in only 2-4% of patients. Conversely, nephrollevel <2.5 mmol/l, and serum creatinine <300 mmol/l ogists mainly publish series of acute [7, [20] [21] [22] or severe at presentation. Results on survival when multidrug renal failure [3, 6, 8, 9] . Such discrepancies might stem chemotherapy had been used were of borderline from the nosologic definition of myeloma. Some diasignificance (Table 8) .
gnose as 'myeloma' patients with a full-blown clinical picture, including osteolytic lesions. Others extend the definition to a wider range of monoclonal gammoDiscussion pathies, considering that a monoclonal serum component necessarily indicates that a plasma cell neoplasm is Renal function at work, even when the site of malignant cell proliferation has not been localized [18]. Alexanian and Dimopoulos [17] indicated that renal function is impaired in approximately 20% of patients It is usually considered that in MG renal failure dialysis, renal failure is no longer an inescapable cause of death. Thus, the question today is that of survival during the course of haemodialysis. Some reports contend that end-stage renal failure entails worse prognosis in plasma cell malignancy [6, 7, 9, 20] . Iggo et al. [4] found that one-year survival was 45% in case of ESRD vs 66% of patients who did not require dialysis, although no difference was found when patients were stratified according to staging. Others concluded to only trivial differences in survival whether patients were or not dialysed [3, 5, 8, 22] . One-year survival was 53% in the series of Cosio et al. [3] and 54% in an American report on 731 patients with myeloma who started renal replacement from 1983 to 1985. Further survival fell to 25% at 20 months vs 66% for other, non-diabetic, ESRD patients [5] . The overall survival rate was not better in our series. survival more specifically depends on three factors: the pattern of lesions observed on renal biopsy, the tumour [8, 12] . The high percentage of AL-amyloidosis with MM reported here (29.7%) may be explained by liberal indication of renal biopsy and non inclusion of AL amyloidosis in most series dealing with MM [3, 4, 7, 9] . In our experience, median survival was only one year in MK but reached 2 years in AL-amyloidosis and 4 years in LCDD patients. Maintenance haemodialysis was started earlier in MK, followed by AL and LCDD, with a survival rate of 6, 22 and 48 months, respectively, after initiation of dialysis.
These results compare favourably with those of the literature. In large series of AL-amyloidosis, median survival rate was 12-13 months [10, 24] and was shorter in patients with than in those without a full-blown picture of multiple myeloma [10] . In 321 patients with amyloidosis requiring dialysis therapy, median survival extended to 21 months after starting dialysis, but AL-amyloidosis was not distinguished from other forms of amyloidosis [5] . The same remark may be portends a poor outcome [18, 23] and that its reversal predicts better prognosis [8, 21] . However, Alexanian applied to the patient population of Moroni et al. [11] , where survival reached 25 months, although no et al. [19] found that, for similar haematological severity, the degree of azotemia did not adversely affect difference in survival was found between AA and AL-amyloidosis patients. prognosis.
In fact, as myeloma patients with reasonable life Ganeval et al. [8] found LCDD in 26.6% of biopsied myeloma patients, an incidence at least as expectancy are now treated with maintenance haemo- also reveal an unsuspected glomerular lesion or a picture different from myeloma cast nephropathy. In addition, the discovery of extensive interstitial fibrosis high as that of AL-amyloidosis and which is underesti-in a renal biopsy specimen is a marker of poor mated if renal biopsy has not been performed. In the prognosis [8] . experience of Pozzi et al. [13] , mean survival was 18
In fact, rather than renal failure, infection is one of months (only 6.5 months in dialysis), but most of the main causes of death in patients with MK, even their patients died from cachexia and multiorgan after the first year of survival [4, 7, 20] . Congestive heart failure and cardiac arrythmias are the main involvement. In patients seen at an earlier stage, causes of death in AL-amyloidosis [24, 26 ] and dialysis any significant predictive factor, except for gender. In patients with severe renal failure, Ganeval et al. [8] does not modify the incidence of such complications [26 ] . This explains why in the series of Gertz et al. found that response to chemotherapy, staging, and renal function one month after diagnosis were the sole [26 ], all long-term survivors had no cardiac involvement by ultrasound examination. elements predicting survival. In an effort to analyse why 10 of 37 patients with myeloma and severe renal The same applies to the rare cases of patients with monoclonal gammopathies and end-stage renal failure failure survived for more than 36 months, Pasquali et al. [7] found a lower incidence of hypercalcaemia, who underwent successful renal transplantation. This was the case for one of our patients who was success-infection, irreversible renal failure and tubulointerstitial damage. Kyle's experience of long-term fully transplanted after 87 months of dialysis, without recurrence of myeloma. There are few reports of renal survivors was different [18] . Of 870 patients with myeloma, 19 survived ten years or more after starting transplantation in myeloma. Reviewing the literature, Iggo et al. [4] found in 10 patients a mean survival chemotherapy. The factors for such long-term survival were positive response to therapy, young age and rate of 31.5 months after transplantation. Only anecdotal reports of long-term renal grafting are absence of renal insufficiency.
Few studies have used multivariate analysis. known in patients with AL-amyloidosis [31] .
Tsuchiya et al. [31] found that pre-treatment factors related to long-term survival were young age and low Tumour cell mass and chemotherapy tumor mass. In our experience, multivariate analysis showed that, in addition to low tumor mass, age under A high tumour cell mass was found in only one-third of our patients, which is less than in other series [8] , 70, serum calcium less than 2.5 mmol/l and serum creatinine less than 300 mmol/l were the best independand this might explain a more favourable prognosis. Kaplan and Meier's curves showed that, in dialysis ent predictors of survival. In our hands, there was a trend to better survival with multidrug chemotherapy, MM patients, median survival was correlated with initial tumor cell mass. This is in accordance with the but the figure did not reach statistical significance. We interpret this as being due to the fact that such an findings of Ganeval et al. [8] .
In the experience of many, response to chemotherapy aggressive regimen was administered to old patients with a high grade staging. is the main prognostic factor [4, 8, 18, 21] . In Alexanian's experience [17] , an aggressive multidrug regimen produced better objective responses but Conclusion median survival rates were similar to those of patients receiving only melphalan and prednisone. In our diaOur results underline the value of initial renal biopsy lysed patients treated with multidrug chemotherapy, findings in patients with monoclonal gammopathies, there was a trend to increasing early mortality, but in addition to standard clinical and haematological overall survival was better than when treatment concriteria. We confirm that renal replacement therapy is sisted of melphalan and prednisone. Moreover, conwarranted in non-elderly patients, particularly if renal sidering our whole population, ESRD was less frequent biopsy discloses LCDD or AL-amyloidosis and if the in those treated with multidrug therapy.
disease is discovered at an early stage. In this subgroup Renal function and nephrotic syndrome, when preof patients, multidrug therapy tends to prolong survival sent, may improve or remain stable after chemotherapy and to slow the progression towards ESRD. The in AL-amyloidosis with MM [24] and survival is continuing progress in the treatment of myeloma significantly longer (25) . Ganeval et al. [12] analysed raises the prospect of long-term survival on dialysis the outcome of 10 patients with LCDD. All untreated despite renal death and even of successful renal patients ended in ESRD within 2-22 months, whereas transplantation. the renal function of those treated with chemotherapy stabilized or improved. Four of our patients were
